Institutional shares held 60.3 Million
2.25M calls
1.18M puts
Total value of holdings $5.44B
$203M calls
$106M puts
Market Cap $5.39B
59,719,600 Shares Out.
Institutional ownership 101.0%
# of Institutions 351


Latest Institutional Activity in BPMC

Top Purchases

Q3 2024
Wellington Management Group LLP Shares Held: 3.96M ($358M)
Q3 2024
State Street Corp Shares Held: 2.77M ($250M)
Q3 2024
Jacobs Levy Equity Management, Inc Shares Held: 496K ($44.8M)
Q3 2024
Clearbridge Investments, LLC Shares Held: 482K ($43.5M)
Q3 2024
Squarepoint Ops LLC Shares Held: 224K ($20.3M)

Top Sells

Q3 2024
Rock Springs Capital Management LP Shares Held: 769K ($69.4M)
Q3 2024
Holocene Advisors, LP Shares Held: 16.9K ($1.53M)
Q3 2024
Price T Rowe Associates Inc Shares Held: 5.39M ($487M)
Q3 2024
Woodline Partners LP Shares Held: 454K ($41M)
Q3 2024
Alkeon Capital Management LLC Shares Held: 719K ($64.9M)

About BPMC

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.


Insider Transactions at BPMC

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
495K Shares
From 28 Insiders
Grant, award, or other acquisition 200K shares
Exercise of conversion of derivative security 295K shares
Sell / Disposition
423K Shares
From 13 Insiders
Open market or private sale 423K shares

Track Institutional and Insider Activities on BPMC

Follow Blueprint Medicines Corp and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells BPMC shares.

Notify only if

Insider Trading

Get notified when an Blueprint Medicines Corp insider buys or sells BPMC shares.

Notify only if

News

Receive news related to Blueprint Medicines Corp

Track Activities on BPMC